Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,348 matching trials from the live ClinicalTrials.gov search.
Filters: New Haven, Connecticut Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

NCT03978143
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 31, 2026, 8:09 AM EDT
Recruiting Phase 3 Interventional

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Elritercept, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
25
States / cities
Duarte, California • Glendale, California • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Terminated Not applicable Interventional Results available

Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia

NCT02046226
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Oxygenesys(TM) Dissolved Oxygen Dressing
Device
Lead sponsor
Halyard Health
Industry
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 31, 2026, 8:09 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

NCT02439970
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
Brincidofovir, Valganciclovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 31, 2026, 8:09 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT06481306
View directory record Official record
Conditions
Anemia, Sickle Cell, Healthy Volunteers
Interventions
BMS-986470, Placebo, Famotidine, Pantoprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • Oakland, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

NCT03419234
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
665
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

NCT01769443
View directory record Official record
Conditions
Primary Heart Transplant, Heart Transplantation, Heart Transplant
Interventions
bortezomib, plasmapheresis
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Beverly Hills, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

NCT03490032
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
[68Ga]-PSMA-R2
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 31, 2026, 8:09 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Tolerability of BHV-7000

NCT06443463
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
115
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Exercise and Behavioral Therapy Trial (EBT).

NCT00007748
View directory record Official record
Conditions
Persian Gulf Syndrome
Interventions
Aerobic exercise, Cognitive behavioral therapy
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
28
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia

NCT01769274
View directory record Official record
Conditions
Inherited Erythromelalgia
Interventions
PF-05089771, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 78 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 31, 2026, 8:09 AM EDT
Terminated Phase 1 Interventional Results available

A Study of LY3405105 in Participants With Advanced Cancer

NCT03770494
View directory record Official record
Conditions
Solid Tumor
Interventions
LY3405105
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Fayetteville, Arkansas • New Haven, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 31, 2026, 8:09 AM EDT
Active, not recruiting No phase listed Observational

CREST-2 Long-term Observational Extension Study

NCT05465122
View directory record Official record
Conditions
Stenoses, Carotid
Interventions
Carotid Endarterectomy, FDA-approved carotid stents, Intensive Medical Management
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
2,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

NCT06568731
View directory record Official record
Conditions
Obesity
Interventions
Danuglipron
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 31, 2026, 8:09 AM EDT
Recruiting Not applicable Interventional

Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe

NCT06825897
View directory record Official record
Conditions
Stroke, Acute
Interventions
Conventional Triage for Mechanical Thrombectomy, Direct Transfer to Angiography Suite (DTAS
Other
Lead sponsor
Santiago Ortega Gutierrez
Other
Eligibility
18 Years and older
Enrollment
2,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
New Haven, Connecticut • Hollywood, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

NCT03365882
View directory record Official record
Conditions
Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage III Colon Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pertuzumab, Trastuzumab, HER-2 testing
Biological · Drug · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
786
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Terminated Not applicable Interventional

EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)

NCT04391803
View directory record Official record
Conditions
Intracranial Aneurysm, Ruptured Aneurysm
Interventions
Pipeline™ Flex Embolization Device with Shield Technology™
Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
22 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Marietta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

NCT03130556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, High Fat, High Calorie Meal, Rabeprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 31, 2026, 8:09 AM EDT
Completed No phase listed Observational Results available

Post-Market Surveillance With a Novel mHealth Platform

NCT03436082
View directory record Official record
Conditions
Gastrectomy, Atrial Fibrillation
Interventions
A mobile health platform
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 31, 2026, 8:09 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Tebapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Lakewood, California • Los Angeles, California • Redlands, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 8:09 AM EDT
Completed No phase listed Observational

The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants

NCT03535883
View directory record Official record
Conditions
Pleural Effusion, Thoracic Effusion
Interventions
Novel Oral Anti-Coagulants
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

NCT00049751
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Apple Valley, California • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 31, 2026, 8:09 AM EDT
Completed Not applicable Interventional

HIV Testing and Brief Alcohol Intervention for Young Drinkers in the Emergency Department

NCT01573065
View directory record Official record
Conditions
Alcohol Consumption, Sexual Risk Behaviors
Interventions
Counseling intervention with rapid HIV testing
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 31, 2026, 8:09 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

NCT03737981
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
857
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 8:09 AM EDT